NasdaqGM:IOVABiotechs
A Look At Iovance Biotherapeutics (IOVA) Valuation After New Real World Amtagvi Efficacy Data
Iovance Biotherapeutics (IOVA) is back in focus after real world data for its recently approved Amtagvi therapy showed a 44% confirmed objective response rate and 73% disease control in advanced melanoma patients.
See our latest analysis for Iovance Biotherapeutics.
Those Amtagvi results come as Iovance’s 7 day share price return of 11.67% and 90 day share price return of 14.80% contrast with a 1 year total shareholder return decline of roughly 50%. Recent momentum is improving from a weak...